Published in Antimicrob Agents Chemother on June 01, 1999
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev (2001) 15.81
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol (2000) 2.71
Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis (2001) 2.59
Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother (2002) 2.08
Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol (2006) 2.06
Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol (2000) 1.83
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? J Clin Microbiol (1998) 1.56
Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method. J Clin Microbiol (2003) 1.46
Modification of the double-disk test for detection of enterobacteriaceae producing extended-spectrum and AmpC beta-lactamases. J Clin Microbiol (2003) 1.34
Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases. J Clin Microbiol (2007) 1.14
Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob Agents Chemother (2001) 1.12
Recent developments in beta lactamases and extended spectrum beta lactamases. BMJ (2003) 1.11
Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J Clin Microbiol (2006) 1.07
Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. Antimicrob Agents Chemother (1999) 0.96
Nosocomial blood stream infection in intensive care units at Assiut University Hospitals (Upper Egypt) with special reference to extended spectrum beta-lactamase producing organisms. BMC Res Notes (2009) 0.95
Extended-spectrum beta-lactamases in Ireland, including a novel enzyme, TEM-102. Antimicrob Agents Chemother (2003) 0.88
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India. Indian J Med Res (2012) 0.76
BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae. J Clin Microbiol (2002) 0.75
Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam. J Clin Diagn Res (2016) 0.75
Evaluation of efficiency of screening extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in hospitals where the bacteria are increasingly prevalent. J Clin Microbiol (2001) 0.75
A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother (1995) 26.51
The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol (1975) 19.91
Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis (1988) 17.69
beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev (1995) 12.53
More extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1991) 11.28
Extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1989) 8.34
Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins. Antimicrob Agents Chemother (Bethesda) (1968) 8.23
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother (1997) 7.07
A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection (1991) 6.78
Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother (1990) 6.11
Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet (1987) 5.45
Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother (1986) 4.73
Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae. Antimicrob Agents Chemother (1990) 4.45
Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother (1996) 4.41
Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection (1990) 3.80
Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother (1992) 3.31
Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother (1996) 3.20
Plasmid-mediated AmpC-type beta-lactamase isolated from Klebsiella pneumoniae confers resistance to broad-spectrum beta-lactams, including moxalactam. Antimicrob Agents Chemother (1993) 3.19
Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated beta-lactamase with two molecular variants. Antimicrob Agents Chemother (1994) 3.09
Characterization of a plasmid-borne and constitutively expressed blaMOX-1 gene encoding AmpC-type beta-lactamase. Gene (1994) 3.08
Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1990) 2.83
Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes. Antimicrob Agents Chemother (1996) 2.77
Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2). Antimicrob Agents Chemother (1996) 2.74
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother (1995) 2.62
Characterization of the plasmid mediated beta-lactamase BIL-1. J Antimicrob Chemother (1992) 2.48
Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol (1994) 2.47
Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis (1996) 2.40
Identification of a novel plasmid-mediated beta-lactamase with chromosomal cephalosporinase characteristics from Klebsiella pneumoniae. J Antimicrob Chemother (1993) 2.37
Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol (1996) 2.23
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol (1997) 2.15
Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob Agents Chemother (1997) 2.05
Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors. J Antimicrob Chemother (1992) 2.04
Epidemiology of extended spectrum beta-lactamases. Infection (1990) 1.67
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother (1994) 1.64
Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains. J Antimicrob Chemother (1996) 1.64
TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain. FEMS Microbiol Lett (1992) 1.62
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? J Clin Microbiol (1998) 1.56
Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol (1997) 1.54
Incidence of strains producing extended spectrum beta-lactamases in Argentina. Infection (1990) 1.51
Is it important to identify extended-spectrum beta-lactamase-producing isolates? Eur J Clin Microbiol Infect Dis (1996) 1.49
First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother (1995) 1.40
Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Curr Clin Top Infect Dis (1996) 1.40
Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals. Eur J Clin Microbiol Infect Dis (1989) 1.36
Plasmid-mediated production of class I (AmpC) beta-lactamase by two Klebsiella pneumoniae isolates from the UK. J Antimicrob Chemother (1995) 1.25
Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother (1991) 1.13
A simple and reliable method to screen isolates of Escherichia coli and Klebsiella pneumoniae for the production of TEM- and SHV-derived extended-spectrum beta-lactamases. Clin Microbiol Infect (1997) 1.11
Production of a plasmid mediated AmpC-like beta-lactamase by a Klebsiella pneumoniae septicaemia isolate. J Antimicrob Chemother (1994) 1.10
Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. Antimicrob Agents Chemother (1999) 0.96
Problems with detection of beta-lactam resistance among nonfastidious gram-negative bacilli. Infect Dis Clin North Am (1993) 0.90
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother (1984) 6.81
Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis (1983) 5.57
Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases. Antimicrob Agents Chemother (1979) 4.93
Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother (1986) 4.73
Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev (1997) 4.32
Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother (2004) 3.82
beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother (1998) 3.76
Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother (1992) 3.31
Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis (1986) 2.73
Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol (2000) 2.71
Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae. J Infect Dis (1982) 2.71
ampG is essential for high-level expression of AmpC beta-lactamase in Enterobacter cloacae. Antimicrob Agents Chemother (1989) 2.63
A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis (1990) 2.63
Purification and characterization of inducible beta-lactamases in Aeromonas spp. Antimicrob Agents Chemother (1990) 2.60
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother (1982) 2.58
Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. J Infect Dis (1985) 2.56
In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother (1982) 2.54
Novel resistance selected by the new expanded-spectrum cephalosporins: a concern. J Infect Dis (1983) 2.49
Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des (1999) 2.31
Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol (1996) 2.23
Molecular characterization of a multiply resistant Klebsiella pneumoniae encoding ESBLs and a plasmid-mediated AmpC. J Antimicrob Chemother (1999) 2.15
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol (1997) 2.15
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2001) 2.10
Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains. Antimicrob Agents Chemother (1998) 2.03
Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol (2000) 1.83
Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital. J Clin Microbiol (2001) 1.78
Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis (1988) 1.74
Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance. Diagn Microbiol Infect Dis (1992) 1.74
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (1999) 1.73
Role of beta-lactamases and outer membrane proteins in multiple beta-lactam resistance of Enterobacter cloacae. Antimicrob Agents Chemother (1985) 1.72
Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens. J Infect Dis (1986) 1.71
Characterization of beta-lactamase induction in Enterobacter cloacae. Antimicrob Agents Chemother (1983) 1.69
BL-P1654: a bacteriostatic penicillin? Antimicrob Agents Chemother (1975) 1.67
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam? J Clin Microbiol (1998) 1.56
Selective ceftazidime resistance in Escherichia coli: association with changes in outer membrane protein. J Infect Dis (1987) 1.55
High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, Ohio. Antimicrob Agents Chemother (1991) 1.55
Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol (1997) 1.54
Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis (1982) 1.54
New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis. Antimicrob Agents Chemother (1995) 1.53
In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 1.52
Inhibition of Neisseria gonorrhoeae by aerobic and facultatively anaerobic components of the endocervical flora: evidence for a protective effect against infection. Infect Immun (1978) 1.52
Beta-lactam resistance in Aeromonas spp. caused by inducible beta-lactamases active against penicillins, cephalosporins, and carbapenems. Antimicrob Agents Chemother (1988) 1.49
Emergence of resistance to imipenem in Enterobacter isolates masquerading as Klebsiella pneumoniae during therapy with imipenem/cilastatin. Clin Infect Dis (1993) 1.48
Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1999) 1.46
Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp. Antimicrob Agents Chemother (1997) 1.44
Altered phenotypes associated with ampD mutations in Enterobacter cloacae. Antimicrob Agents Chemother (1991) 1.42
Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice. J Antibiot (Tokyo) (1978) 1.41
Bacterial interference: effects of oral antibiotics on the normal throat flora and its ability to interfere with group A streptococci. Infect Immun (1976) 1.40
Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Curr Clin Top Infect Dis (1996) 1.40
In vitro activity of rosamicin against Neisseria and Haemophilus, including penicillinase-producing strains. Antimicrob Agents Chemother (1977) 1.36
In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother (1991) 1.35
Inducible beta-lactamases and non-hydrolytic resistance mechanisms. J Antimicrob Chemother (1984) 1.35
Synergy of penicillin-netilmicin combinations against enterococci including strains highly resistant to streptomycin or kanamycin. Antimicrob Agents Chemother (1977) 1.34
Overview of preclinical studies with ciprofloxacin. Am J Med (1987) 1.32
Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis. J Infect Dis (1987) 1.31
Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother (1990) 1.30
Diverse potential of beta-lactamase inhibitors to induce class I enzymes. Antimicrob Agents Chemother (1990) 1.27
Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam. Antimicrob Agents Chemother (1992) 1.26
Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother (1999) 1.25
In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother (1978) 1.23
Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam. Antimicrob Agents Chemother (1993) 1.22
Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs. J Clin Microbiol (2009) 1.20
Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med (1997) 1.17
Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides. Antimicrob Agents Chemother (1976) 1.16
New beta-lactams: new problems for the internist. Ann Intern Med (1991) 1.15
Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 1.12
Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1986) 1.11
Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol (1987) 1.10
Antibiotic resistance. Epidemiology and therapeutics. Diagn Microbiol Infect Dis (1992) 1.09
Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrob Agents Chemother (1988) 1.08
Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics. Antimicrob Agents Chemother (1995) 1.08
Colonization with penicillin-nonsusceptible Streptococcus pneumoniae in urban and rural child-care centers. Pediatr Infect Dis J (1996) 1.07
Failure to adopt new interpretive criteria for ticarcillin-clavulanic acid could prove fatal. Antimicrob Agents Chemother (1992) 1.07
beta-Lactam resistance amongst Enterobacter species. J Antimicrob Chemother (1993) 1.07
Imipenem resistance in Enterobacter. Eur J Clin Microbiol Infect Dis (1993) 1.06
Accuracy of microdilution and the AutoMicrobic System in detection of beta-lactam resistance in gram-negative bacterial mutants with derepressed beta-lactamase. Rev Infect Dis (1988) 1.05
Sequencing and analysis of four new Enterobacter ampD Alleles. Antimicrob Agents Chemother (1996) 1.03
Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob Agents Chemother (1997) 1.03
A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol (2000) 1.03
Antagonism of carbenicillin and cefamandole by cefoxitin in treatment of experimental infections in mice. Antimicrob Agents Chemother (1982) 1.01
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (2001) 0.99
Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections. Antimicrob Agents Chemother (1983) 0.99
Decimal assay for additivity of drugs permits delineation of synergy and antagonism. Antimicrob Agents Chemother (1993) 0.99
Isolation of Enterobacter aerogenes susceptible to beta-lactam antibiotics despite high level beta-lactamase production. Eur J Clin Microbiol Infect Dis (1990) 0.99
USA resistance patterns among UTI pathogens. J Antimicrob Chemother (1994) 0.99
Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis (1996) 0.98
Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. Antimicrob Agents Chemother (1999) 0.96
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother (1999) 0.95
Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother (1997) 0.95
Long term epidemiological analysis of Citrobacter diversus in a neonatal intensive care unit. Pediatr Infect Dis J (1992) 0.94
Vitamin B6-dependent Streptococcus mimicking fungi in a patient with endocarditis. Am J Clin Pathol (1983) 0.94